AbCellera Biologics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- AbCellera Biologics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- British Columbia, Canada
- Headquarters city
- Vancouver
- Headquarters country
- Canada
- Fiscal year end
- December
- Ticker symbol
- ABCL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001703057
Board of directors
-
Andrew Lo · DirectorSince 2024
-
Carl L. G. Hansen · Director · Chief Executive OfficerSince 2023
-
John S. Montalbano · DirectorSince 2023
-
Lynn Seely · DirectorSince 2026
-
Michael R. Hayden · DirectorSince 2023
-
Stephen Quake · DirectorSince 2025
-
Veronique Lecault · Director · Chief Technology OfficerSince 2023
-
Victor Sandor · DirectorSince 2026
Chief executives
Carl L. G. Hansen
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.8%
Board connections
4 of this board's directors also sit on 6 other boards.
- via Victor Sandor
- via Andrew Lo
- via Michael R. Hayden
- via Victor Sandor
- via Lynn Seely
- via Victor Sandor
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,676,276
- 9 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 24, 2026 | Michael R. Hayden Director | Open-market purchase | +53,613 | $10.64 | $570,442 |
| Aug 18, 2026 | John S. Montalbano Director | Open-market purchase | +10,000 | $11.03 | $110,300 |
| Aug 14, 2026 | Booth Andrew Officer (Chief Financial Officer) | Open-market purchase | +37,200 | $10.32 | $383,904 |
| Aug 12, 2026 | Michael R. Hayden Director | Open-market purchase | +46,387 | $10.37 | $481,033 |
| Aug 11, 2026 | Michael R. Hayden Director | Gift | −50,000 | — | — |
| Jun 3, 2026 | Booth Andrew Officer (Chief Financial Officer) | Option exercise | +250,000 | $0.19 | $47,500 |
| May 14, 2026 | John S. Montalbano Director | Open-market purchase | +20,000 | $4.77 | $95,400 |
| Feb 27, 2026 | Thermopylae Holdings Ltd. 10% owner | Open-market purchase | +38,000 | $3.44 | $130,720 |
| Feb 27, 2026 | Booth Andrew Officer (Chief Financial Officer) | Open-market purchase | +42,600 | $3.42 | $145,692 |
| Feb 26, 2026 | Thermopylae Holdings Ltd. 10% owner | Open-market purchase | +177,457 | $3.27 | $580,284 |
| Dec 18, 2025 | Thermopylae Holdings Ltd. 10% owner | Gift | −225,000 | — | — |
| Nov 26, 2025 | John S. Montalbano Director | Open-market purchase | +50,000 | $3.57 | $178,500 |
| Mar 11, 2025 | Thermopylae Holdings Ltd. 10% owner | Open-market purchase | +343,631 | $2.16 | $742,243 |
| Mar 10, 2025 | John S. Montalbano Director | Open-market purchase | +25,000 | $2.30 | $57,500 |
| Mar 6, 2025 | John S. Montalbano Director | Open-market purchase | +60,000 | $2.34 | $140,400 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.